425: Kintara Therapeutics and TuHURA Biosciences Announce IFx-2.0 Clinical Trial Results Presentation at ASCO and Update on Merger

TuHURA Biosciences' IFx-2.0 Phase 1b clinical trial results have been accepted for poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting, coinciding with updates on the proposed merger with Kintara Therapeutics.

Summary

• TuHURA Biosciences announced that its IFx-2.0 Phase 1b clinical trial results have been accepted for a poster presentation at the 2024 ASCO Annual Meeting.
• The trial focused on IFx-2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma.
• TuHURA and Kintara Therapeutics have entered into a definitive agreement for an all-stock merger to advance a diversified oncology pipeline.
• TuHURA also entered into subscription agreements for $31 million in financing.
• The combined company is expected to operate under the name TuHURA Biosciences, Inc. and trade on The Nasdaq Capital Market under the ticker HURA.
• The merger is expected to close in the third quarter of 2024, subject to customary closing conditions, including stockholder approval.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the clinical trial results presentation and the planned merger, which could create a stronger company. However, risks associated with the merger and clinical development temper the overall sentiment.

Positives

• TuHURA's IFx-2.0 clinical trial results being accepted for presentation at ASCO validates the potential of the cancer vaccine.
• The merger between TuHURA and Kintara aims to create a stronger entity with a diversified oncology pipeline.
• The $31 million financing secured by TuHURA will support the advancement of its technologies.
• The combined company will focus on innovative approaches to overcome resistance to cancer immunotherapy.

Risks

• The merger is subject to customary closing conditions, including stockholder approval, which may not be obtained.
• Delays in closing could impact the anticipated cash resources of the combined company.
• The combined company's ability to correctly estimate operating expenses and merger-related costs is uncertain.
• The success of the combined business is not guaranteed and is subject to various factors, including competitive responses and regulatory developments.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The combined company will focus on advancing TuHURA's personalized cancer vaccines and first-in-class bi-functional Antibody Drug Conjugates (ADCs). The merger is expected to close in the third quarter of 2024.

Industry Context

The announcement highlights the ongoing interest and investment in immuno-oncology and personalized cancer vaccines, reflecting a broader industry trend towards developing novel therapies to overcome resistance to existing treatments. The merger between Kintara and TuHURA is part of a larger trend of consolidation in the biotech industry to create companies with more diversified pipelines and resources.

Comparison to Industry Standards

• TuHURA's IFx-2.0 personalized cancer vaccine is designed to compete with existing checkpoint inhibitors like Keytruda (pembrolizumab) by addressing primary resistance.
• The development of bi-functional ADCs targeting Myeloid Derived Suppressor Cells aligns with industry efforts to enhance the tumor microenvironment and prevent T cell exhaustion, similar to approaches being pursued by companies like Bristol Myers Squibb and AstraZeneca.
• The Phase 3 registration trial planned for IFx-2.0 in Merkel Cell Carcinoma mirrors the development pathway of other cancer vaccines, such as Provenge for prostate cancer, which demonstrated improved survival outcomes in clinical trials.

Stakeholder Impact

• Shareholders of both Kintara and TuHURA will be impacted by the proposed merger, requiring them to vote on the transaction.
• Employees of both companies may experience changes as a result of the merger.
• Patients with Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma could benefit from the development of IFx-2.0.
• The merger could impact the competitive landscape in the immuno-oncology space.

Next Steps

• Kintara will file a Registration Statement on Form S-4 with the SEC, including a proxy statement/prospectus.
• Kintara will send a definitive proxy statement/prospectus to its stockholders.
• Stockholder approval will be sought for the proposed merger.
• The merger is expected to close in the third quarter of 2024.
• TuHURA will present its IFx-2.0 Phase 1b clinical trial results at the 2024 ASCO Annual Meeting.

Key Dates